Forward-looking information is subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Many of these factors are beyond the Company’s ability to control or predict. Important factors that may cause actual results to differ materially and that could impact the Company and the statements contained in this news release can be found in the Company’s filings with the Securities and Exchange Commission. For forward-looking statements in this new release, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.
Bovie Medical Corporation (the “Company”) (NYSE-AMEX Symbol: BVX), a manufacturer and marketer of electrosurgical products, today announced the appointment of Jeff Rencher as vice president of sales and marketing for surgical products. Mr. Rencher joins Bovie with over 16 years of medical products sales experience. He is skilled in hiring and managing direct and independent sales representatives for both new and established medical products. In the past, Mr. Rencher has also been responsible for advertising, forecasting, marketing and trade shows for surgical and non-surgical medical products. Andrew Makrides, president of Bovie, stated, “Jeff’s vast experience in increasing medical product sales through building direct and indirect sales teams will be a valuable addition to our management team. ” An employment agreement with Mr. Rencher was entered into on June 25, 2010, and as part thereof, he was awarded a restricted non-qualified stock option for an aggregate of 30,000 shares of common stock, exercisable at $6 per share. The option has a ten year term and will vest upon the achievement of key sales objectives. This press release is issued in accordance with the exemption afforded under Section 711(a) of the NYSE AMEX Company Guide which exempts certain stock option grants made as an inducement to employment from the stockholder approval requirement. For further information about the Company’s current and new products, please refer to the Investor Relations section of Bovie’s website www.boviemedical.com. Certain matters discussed in this news release and oral statements made from time to time by representatives of the Company may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Although the Company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, it can give no assurance that its expectations will be achieved.